Post-Approval Change Submissions

Freyr simplifies post-approval changes, providing expert Regulatory support for CMC changes, lifecycle maintenance, and compliance strategies. Ensure your pharmaceutical products meet global standards with our dedicated services.

Post-Approval Change Submissions - Overview

To enhance productivity and optimize operational costs, medicinal product manufacturers propose certain changes to the registered content of the medicinal product applications/dossiers. Any changes in the registered content of medicinal products including those related to Post Approval Regulatory Affairs, should be submitted to the respective Health Authority (HA) per the appropriate submission procedure with supporting data before its implementation. Based on the impact of the change, the prior approval requirements would be determined about the CMC post-approval change submissions (post-approval supplements/amendments/CMC variations) guidelines of the respective HAs. In this phase, the importance of the Regulatory strategy for post-approval change submission is significant.

Freyr’s CMC Regulatory Affairs team has experience and expertise in handling the following CMC post-approval change submissions to and the competent HAs based on country-specific requirements.

Furthermore, Regulatory Compliance Associates offer post-market surveillance, Post Approval Regulatory Affairs services, Post-Approval Submissions and Lifecycle Maintenance, ANDA Post-Approval Changes, and various other services to maintain compliance with Regulatory requirements.

Post-Approval Change Submissions

  • Change in the manufacturing site like an addition/deletion
  • Marketing Authorization Holder transfers
  • Optimization of manufacturing process/change in route of synthesis/change in equipment
  • Change in formulation/batch size change
  • Addition of new supplier for active substance/CEP updates/new CEP
  • Inclusion of additional sources for the starting material of the drug substance
  • Post-approval changes to drug substances
  • Post-approval Regulatory affairs and services are for maintaining compliance and ensuring the quality, safety, and efficacy of approved pharmaceutical products
  • Monograph updates, i.e., CMC Regulatory compliance to pharmacopeia
  • Specifications and analytical method changes
  • Changes in container closure system and suppliers
  • Shelf-life extension/reduction
  • Administrative updates/contact details’ changes
  • Change controls/proposed changes evaluation
  • Provide CMC consulting on the submission strategy for the proposed changes
  • Implementation strategy and timelines
  • Guidance in supporting documents/data
  • Preparation of Supplement/Variation/Amendment Package
  • Interaction and follow-ups with Health Authorities for approval and implementation
  • CMC Regulatory compliance of legacy dossiers/submissions with post-approval supplements/CMC variations
  • CMC post-approval Regulatory affairs
  • Support in CMC post-approval changes
  • Post-approval Regulatory Affairs and Consultation Services
  • FDA post-approval changes submission strategy
  • Up-to-date post-approval changes guidelines
  • Timely filing of CMC Regulatory submissions
  • Post-approval submissions and lifecycle maintenance support

Avail Expert Consultation in CMC Post-approval Changes

Celebrating Customers Success

 

Medicinal Products

Regulatory Affairs

India

Thank you for the timely support over the weekend, which allowed us to resubmit quickly after being notified. This continuously demonstrates Freyr's commitment towards our company’s milestones.

Director - Global Regulatory Affairs – Operations

India-based, Global Top Generic Pharma Company

 

Medicinal Products

Publishing

UK

I am sure you have heard by now that we have received our first-ever approval from the FDA for our Brands division. This is a major milestone for us as well as for my team here in Reg Ops. I would be remiss if I didn’t point out that we would not have been able to do this without the help of your dedicated team. From the original filing, then the following year of responses, all helped get us to final approval.

Thank you Freyr team for a job well done!

Sr. Director, Head of Regulatory Operations

Ireland-based, Global Specialty Pharmaceutical Company

 

Medicinal Products

Regulatory Affairs

USA

Please relate to the team the excellent job they have done on the IND reactivation. Specifically, the high-quality module 3, written by Freyr. It was very comprehensive, very few revisions were required, and we had no questions from Health Canada or FDA. No CMC questions: that was a first for me. So very responsive to my many requests, which I am sure can be frustrating but always helpful while producing excellent work.

Thank you for always being available and responding quickly and comprehensively to all my requests.

What a great team you have, Freyr.

Lynne McGrath

Regulatory Consultant

 

Medicinal Products

Regulatory Affairs

USA

Congratulations!!! ​

Thanks for your great support for a successful ANDA filing, especially to the publishing team. Heartfully appreciate their last hours of hard work.

Assistant Manager​

US-based, Leading, Complex Generic Pharmaceutical Products Company​

 

Medicinal Products

Regulatory Affairs

USA

Thank you all for the great support!​

CEO

US-based, Leading Innovative Pharmaceuticals Company​

 

Medicinal Products

Regulatory Affairs

USA

The ANDA receipt has been received! Thank you very much for your hard work, patience, and support for our work over the last couple of months. We are delighted that we were able to meet the timeline and hit an important corporate goal of our young company. ​

Thank you again, and we look forward to working with your team on the next project!

Senior Director of Business and Product Development​

US-based, Leading Innovator Pharmaceuticals Company​